← Back to Search

Procedure

TIVUS™ System for Pulmonary Hypertension (TROPHY 1-US Trial)

N/A
Waitlist Available
Research Sponsored by SoniVie Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2, 3, 4 and 5 years
Awards & highlights

TROPHY 1-US Trial Summary

This trial will study the safety and effectiveness of the TIVUS™ System for treating pulmonary artery hypertension. Up to 15 patients will be enrolled in this prospective, open-label study at 4 centers.

Eligible Conditions
  • Pulmonary Arterial Hypertension

TROPHY 1-US Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2, 3, 4 and 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2, 3, 4 and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Amount of all procedural related adverse event as assessed by the CEC
Amount of treatment related adverse event as assessed by the CEC
Number of patient with PAH worsening and all cause death events
Secondary outcome measures
Clinical effectiveness
Clinical efffectivness
Other outcome measures
Observational Variables
Observational Variables - Long term surveillance

TROPHY 1-US Trial Design

1Treatment groups
Experimental Treatment
Group I: Pulmonary DenervationExperimental Treatment1 Intervention
Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.

Find a Location

Who is running the clinical trial?

SoniVie Inc.Lead Sponsor
4 Previous Clinical Trials
260 Total Patients Enrolled
2 Trials studying Pulmonary Arterial Hypertension
220 Patients Enrolled for Pulmonary Arterial Hypertension

Media Library

Therapeutic Intra-Vascular UltraSound (TIVUS™) System (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT02835950 — N/A
Pulmonary Arterial Hypertension Research Study Groups: Pulmonary Denervation
Pulmonary Arterial Hypertension Clinical Trial 2023: Therapeutic Intra-Vascular UltraSound (TIVUS™) System Highlights & Side Effects. Trial Name: NCT02835950 — N/A
Therapeutic Intra-Vascular UltraSound (TIVUS™) System (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02835950 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other healthcare facilities in the city that are conducting this experiment?

"At the present moment, 4 different clinical trials sites are actively enrolling patients. These locations include San Diego, Ann Arbor and New york as well as other nearby centres - making it prudent to select a site that is closest to you in order to limit your travelling costs if chosen for this study."

Answered by AI

Are there any open slots for enrollment in this medical experiment?

"According to the information available on clinicaltrials.gov, this particular medical study has ceased enrolling new patients since March 30th 2022. However, there are 765 other trials recruiting now for those looking to partake in a trial."

Answered by AI
~2 spots leftby Apr 2025